Status and phase
Conditions
Treatments
About
This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.
Full description
Study TTP399-302 is a 52-week, Phase 3 trial designed to measure the relative efficacy of treatment with cadisegliatin to reduce the incidence of Level 2 or Level 3 hypoglycemia in participants with Type 1 Diabetes Mellitus compared to placebo over 26 weeks of continuous therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Jennifer Freeman, Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal